Vaginal tamoxifen – A potential treatment option for vaginal atrophysymptoms in postmenopausal women who cannot use estrogen Por [email protected] Vaginal tamoxifen – A potential treatment option for vaginal atrophysymptoms in postmenopausal women who cannot use estrogen Read More »
Weight Loss Patterns and Clinical Outcomes ofGLP1 Receptor Agonists in Breast CancerSurvivors Por [email protected] Weight Loss Patterns and Clinical Outcomes ofGLP1 Receptor Agonists in Breast CancerSurvivors Read More »
Obesity and Cancer A Translational Science Review Por [email protected] Obesity and Cancer A Translational Science Review Read More »
CancerVIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER22/ PIK3CA Wild-Type Advanced Breast Cancer Por Adson Machado CancerVIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER22/ PIK3CA Wild-Type Advanced Breast Cancer Read More »
Is Lobular Histology a Predictor of Sentinel Node Positivity in Early Breast Cancer? An Integrated Analysis of Histological Subtype and Preoperative Imaging Por Adson Machado Is Lobular Histology a Predictor of Sentinel Node Positivity in Early Breast Cancer? An Integrated Analysis of Histological Subtype and Preoperative Imaging Read More »
Is Lobular Histologya Predictor of Sentine lNode Positivity in Early BreastCancer?An Integrated Analysis of Histological Subtype and Preoperative Imaging Por [email protected] Is Lobular Histologya Predictor of Sentine lNode Positivity in Early BreastCancer?An Integrated Analysis of Histological Subtype and Preoperative Imaging Read More »
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With orWithout Palbociclib in Hormone Receptor–Positive/HER22/PIK3CA Wild-Type Advanced Breast Cancer Por [email protected] VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With orWithout Palbociclib in Hormone Receptor–Positive/HER22/PIK3CA Wild-Type Advanced Breast Cancer Read More »
Diagnostic accuracy of FDG-PET-CT to predictaxillary lymph node response after neoadjuvant chemotherapy in lymph nodepositive breast cancer patients Por [email protected] Diagnostic accuracy of FDG-PET-CT to predictaxillary lymph node response after neoadjuvant chemotherapy in lymph nodepositive breast cancer patients Read More »
Extended Endocrine Therapy Following 5 Years of AdjuvantLuteinizing Hormone-Releasing Hormone Agonist inPremenopausal Patients With Node-Positive, HormoneReceptor–Positive Breast Cancer: A Cohort Study Por [email protected] Extended Endocrine Therapy Following 5 Years of AdjuvantLuteinizing Hormone-Releasing Hormone Agonist inPremenopausal Patients With Node-Positive, HormoneReceptor–Positive Breast Cancer: A Cohort Study Read More »
Germline Pathogenic Variants AmongWomenWithout a History of Breast Cancer A Secondary Analysis of the WISDOM Randomized Clinical Trial Por Adson Machado Germline Pathogenic Variants AmongWomenWithout a History of Breast Cancer A Secondary Analysis of the WISDOM Randomized Clinical Trial Read More »
Pooled analysis by best confirmed response to trastuzumab deruxtecan andrelated biomarkers in patients with HER2-positive metastatic breast cancerfrom DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 Por Adson Machado Pooled analysis by best confirmed response to trastuzumab deruxtecan andrelated biomarkers in patients with HER2-positive metastatic breast cancerfrom DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 Read More »
Impact of neoadjuvant immunotherapy on postoperative complications inoncoplastic breast cancer surgery Por Adson Machado Impact of neoadjuvant immunotherapy on postoperative complications inoncoplastic breast cancer surgery Read More »
